Lung injury may persist during the recovery period of COVID-19 as shown through imaging,
six-minute walk, and lung function tests. The pathophysiological mechanisms leading to …

The acute respiratory distress syndrome (ARDS) is a life-threatening condition that causes
respiratory failure. Despite numerous clinical trials, there are no molecularly targeted …

Background Geoeconomic variations in epidemiology, the practice of ventilation, and
outcome in invasively ventilated intensive care unit (ICU) patients without acute respiratory …

COVID‐19 is a complex disease, and many difficulties are faced today especially in the
proper choice of pharmacological treatments. The role of antiviral agents for COVID‐19 is …

Objectives: Effective pharmacologic treatments directly targeting lung injury in patients with
the acute respiratory distress syndrome are lacking. Early treatment with inhaled …

Background Statins and aspirin have been proposed for treatment of COVID-19 because of
their anti-inflammatory and anti-thrombotic properties. Several observational studies have …

Abstract Coronavirus disease-2019 (COVID-19) caused by SARS-CoV-2 is an ongoing viral
pandemic marked by increased risk of thrombotic events. However, the role of platelets in …

New findings highlight the complex interplay of innate immunity, coagulation and platelets in
inflammation and infection, and unravel novel molecular pathways and effector functions …

With the exception of a few successes in trials of supportive care, the majority of
interventional clinical trials for acute respiratory distress syndrome (ARDS) have not led to …

Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 is an ongoing viral
pandemic marked by increased risk of thrombotic events. However, the role of platelets in …